


# สถานการณ์เชื่อด้อย่าต้านจุลชีพ ปี 2000-2021(12M)

ศูนย์เฝ้าระวังเชื่อด้อย่าต้านจุลชีพแห่งชาติ (NARST)  
สถาบันวิจัยวิทยาศาสตร์สาธารณสุข กรมวิทยาศาสตร์การแพทย์


<http://narst.dmsc.moph.go.th>

# Antimicrobial Resistance rates of *Enterococcus* spp. by year

## (NARST - 51 hospitals, 12M 2021)




# Rate of vancomycin resistant enterococci



# Percent resistance of *E. faecium*, *E. faecalis* to vancomycin

## *E. faecium*


OPD IPD ICU



Vancomycin


## *E. faecalis*

OPD IPD ICU





Vancomycin

# Antimicrobial Resistance rates of *Staphylococcus spp.* by year (NARST - 51 hospitals, 12M 2021)




# Percent isolates of Methicillin Resistance *S. aureus* (MRSA) and Methicillin Resistance *Staphylococcus* coagulase negative (MRSCN)



# Antimicrobial Resistance rates of *S. pneumoniae* by year

(NARST - 51 hospitals, 12M 2021)




12M 2021 51H


NARST data

# Susceptibility of *S. pneumoniae* by specimen

## Penicillin G (Oxacillin)




## Erythromycin





# Antimicrobial Resistance rates of *Acinetobacter* spp. by year

## (NARST – 51 hospitals, 12M 2021)




12M 2021 51H

NARST data

# Antimicrobial Resistance rates of *P. aeruginosa* by year (NARST - 51 hospitals, 12M 2021)

- Piperacillin/Tazobactam
- Ceftazidime
- Imipenem
- Norfloxacin (UTI)
- Ciprofloxacin
- Amikacin
- Colistin (MIC)




12M 2021 51H

NARST data


CLSI 2019 ไม่กำหนดให้วาง Norfloxacin

# Carbapenem Resistance in *Acinetobacter* spp. and *Pseudomonas aeruginosa*

## *Acinetobacter* spp.




## *Pseudomonas aeruginosa*







# Percent resistance of *A. calcoaceticus*-*baumannii* complex to Imipenem



# Antimicrobial Resistance rates of *E. coli* by year (NARST - 51 hospitals, 12M 2021)




# Antimicrobial Resistance rates of *K. pneumoniae* by year (NARST - 51 hospitals, 12M 2021)



# ESBL producing *E. coli*


Cefotaxime  $R \leq 27$

■ ESBL by screen test



Ceftazidime  $R \leq 22$

■ ESBL by screen test






# ESBL producing *K. pneumoniae*


## Cefotaxime R<sub>≤27</sub>

■ ESBL by screen test




## Ceftazidime R<sub>≤22</sub>


■ ESBL by screen test




# Percentage Resistance of *E. coli* and *K. pneumoniae*



# Carbapenem Resistance in *E. coli* and *K. pneumoniae*




# Percent resistant of **Non-typhoidal Salmonella** isolated from **Blood**, 2000-2021 (12M)




# Percent resistant of *Non-typhoidal Salmonella* isolated from **Stool & Rectal swab**, 2000-2021 (12M)

%R




# Percent resistant of Colistin (2015-2021)



# Antimicrobial Resistance rates of *S. pneumoniae*

## Meningitis



## Non meningitis

